Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

An Early Treatment With BKI-1748 Exhibits Full Protection Against Abortion and Congenital Infection in Sheep Experimentally Infected With Toxoplasma gondii

  • Sánchez Sánchez, Roberto
  • Imhof, Dennis
  • Hecker, Yanina Paola
  • Ferré Pérez, Ignacio
  • Re, Michela Tatiana
  • Moreno Gonzalo, Javier
  • Blanco Murcia, Francisco Javier
  • Mejías López, Elena
  • Hulverson, Matthew A.
  • Choi, Ryan
  • Arnold, Samuel L. M.
  • Ojo, Kayode K.
  • Barrett, Lynn K.
  • Hemphill, Andrew
  • Van Voorhis, Wesley C.
  • Ortega Mora, Luis Miguel
Congenital toxoplasmosis in humans and in other mammalian species, such as small ruminants, is a well-known cause of abortion and fetal malformations. The calcium-dependent protein kinase 1 (CDPK1) inhibitor BKI-1748 has shown a promising safety profile for its use in humans and a good efficacy against Toxoplasma gondii infection in vitro and in mouse models. Ten doses of BKI-1748 given every other day orally in sheep at 15 mg/kg did not show systemic or pregnancy-related toxicity. In sheep experimentally infected at 90 days of pregnancy with 1000 TgShSp1 oocysts, the BKI-1748 treatment administered from 48 hours after infection led to complete protection against abortion and congenital infection. In addition, compared to infected/untreated sheep, treated sheep showed a drastically lower rectal temperature increase and none showed IgG seroconversion throughout the study. In conclusion, BKI-1748 treatment in pregnant sheep starting at 48 hours after infection was fully effective against congenital toxoplasmosis.